natgillin/translations-raw huggingface dataset:
making a first modification of the mouse immunoglobulin heavy chain locus, the first modification comprising the placement of one or more human immunoglobulin gene sequences and/or the replacement of one or more sequences in the mouse immunoglobulin heavy chain locus with one or more human immunoglobulin gene sequences; and, 
Miš u skladu s patentnim zahtjevom 1, naznačen time, da miš ima genom koji sadržava brisanje jednog ili više segmenata varijabilnog područja imunoglobulina miša i umetanje segmenata varijabilnog humanog područja i pri čemu mišu nedostaje funkcionalni endogeni mišji lokus ADAM6.
Kit according to claims 48 to 50, wherein at least one nucleoside triphosphate or one primer is labelled. 
Pribor prema zahtjevima 36 do 42, gdje su najmanje jedan nukleozidni trifosfat ili jedna početnica označeni.
The formulation of claim 2, wherein the neutralizing agent is triethanolamine. The formulation of claim 14, wherein the triethanolamine is present in an amount of 0.35% wt. 
Formulacija prema zahtjevu 2, naznačena time, da navedeno sredstvo za neutraliziranje je trietanolamin, koji je poželjno prisutan u količini od 0.35% tež.
whereupon the compound of formula ID is isolated as the free base or a salt such as a pharmaceutically acceptable acid addition salt thereof. 
Deprotekcija spoja formule XIII Kn o gdje su R!, R*-R'* kako je to ovdje definirano a R' je protekcijska grupa kao karbamati (npr.
Heteromolecular metal complexes (chelates) disclosed in claims 1 or 2, wherein molecule A is a humic acid extracted from one or several sedimentary organic materials (leonardite, lignite or peat) or/and fresh vegetable compost previously treated with hydrogenation and oxidation methods. 
Heteromolekularni metalni kompleksi (kelati) otkriveni u zahtjevima 1 do 7, naznačeni time što je molekula A huminska kiselina izlučena iz jednog ili više sedimentarnih organskih materijala (leonardita, lignita ili treseta) ili/i svježeg povrtnog komposta prethodno tretiranog metodama hidrogenacije i oksidacije.
The compound for use or use of claim 11, wherein the single crystalline form is characterised by x-ray powder diffraction pattern of Figure 1. 
Farmaceutski pripravak prema zahtjevu 3 ili zahtjevu 5, pri čemu je jednostruki kristalinični oblik naznačen time da ima uzorak difrakcije x-zraka na prahu prema slici 1.
The construct for the use of any of claims 1 to 6, wherein for the initial day(s) of an infusion period a lower dose of the CD19xCD3 bispecific single chain antibody construct is to be administered, followed by a higher dose for the remaining infusion period. 
Konstrukt za uporabu prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time što se CD19xCD3 konstrukt protutijela bispecifičnog jednostrukog lanca daje u dnevnoj dozi od 10 µg do 100 µg po kvadratnom metru površine tijela pacijenta.
Embodiments of this invention that comprise an ecteinascidin such as ET-743 are preferably administered by infusion. 
Varijante ovog izuma koje sadrže ekteinascidin kao što je ET-743 poželjno se primjenjuju infuzijom.
0.5% by weight of magnesium stearate; 
0,5% po masi, magnezijevog stearata;
The gaming system of claim 1 further comprising a central server maintaining a database of stored fingerprint data of registered individuals. 
Sustav igranja prema patentnom zahtjevu 1 naznačen time da nadalje sadrži središnji poslužitelj (420) koji održava bazu podataka (160) pohranjenih podataka otisaka prstiju registriranih pojedinaca.
of body weight per day, although variations will necessarily occur depending upon the conditions of the subject being treated and the particular route of administration chosen. 
tjelesne težine na dan, premda će nastati neophodne varijacije ovisno o uvjetima pod kojima se pacijent tretira i o određenom načinu davanja koji je izabran.
is selected from the group consisting of Ser, Thr, DThr and DAla; and 
je odabran iz grupe koja se sastoji od Ser, Thr, DThr i DAla; i
The pharmaceutical composition for use according to claim 21, wherein the myeloproliferative disorder is essential thrombocythemia (ET). 
Spoj ili sol prema zahtjevu 69 naznačen time da navedeni mijeloproliferativni poremećaj (MPD) je esencijalna trombocitemija (ET).
A compound represented by the following formula, a salt thereof or a hydrate of the foregoing: 
Spoj koji je prikazan sa slijedećom formulom, njegova sol ili bidrat navedenog:
The solid dosage form of claim 2, wherein said particles (A) are the product of a process that comprises spray drying a mixture of bardoxolone methyl and a methacrylic acid copolymer. 
Kruti oblik doziranja prema zahtjevu 2, naznačen time da su navedene čestice (A) proizvod postupka koji obuhvaća sušenje raspršivanjem mješavine bardoksolon metila i kopolimera metakrilne kiseline.
Date of analysis 
Datum međunarodne objave:
The method of claim 6, further comprising: outputting the hair cell region image corresponding to the frequency band of the acoustic signal in case that the type of the acoustic signal is the continuous tone or the pulse tone, wherein it is sensed through the hair cell region image that the acoustic signal corresponds to at least one of the continuous tone and the pulse tone. 
– davanja na izlaz slike područja s cilijarnim stanicama koje odgovara frekvencijskom pojasu zvučnog signala u slučaju da je tip zvučnog signala kontinuirani ton ili pulsirajući ton, gdje se osjeća kroz sliku područja s cilijarnim stanicama da zvučni signal odgovara najmanje jednom od kontinuiranog tona i pulsirajućeg tona.
A compound of claim 1 represented by formula XXIV or XXV: wherein G1, G2, n, p, R1, R2 and R8 are as defined in claim 1; 
HO O Formula XXV naznačen time da G;, G>, n, p, Ri, R2 1 Rg su kako je definirano u zahtjevu 1;
The shaped article according to any one of claims 1 to 7, wherein the elastomeric material exhibits a water vapor diffusion barrier property according to EN 12086 of at least µ 2000, preferably at least µ 3000, more preferably at least µ 5000. 
Oblikovani članak (100) prema bilo kojem od patentnih zahtjeva 1 do 7, pri čemu elastomerni materijal pokazuje svojstvo barijere difuzije vodene pare prema EN 12086 od najmanje µ 2000, poželjno barem µ 3000, još poželjnije barem µ 5000.
Such an active immunostimulatory composition allows efficient treatment of non-small lung cancer (NSCLC), or supplementary treatment when using conventional therapies. 
(54) Naziv izuma: PRIPRAVAK RNK ZA LIJEČENJE KARCINOMA PLUĆA NE-MALIH STANICA (NSCLC)
A crystal of the compound according to claim 26. 
Kristal spoja prema zahtjevu 14.
The overpressure was of 300 mbars. 
Tlak je bio 300 mbara.
The production method according to claim 1, wherein the phosphoric acid-activating compound is UMP-imidazolide, and the phosphoric acid compound is a UTP salt. 
Postupak proizvodnje u skladu s patentnim zahtjevom 1, naznačen time, da je spoj za aktivaciju fosforne kiseline UMP-imidazolid, a spoj fosforne kiseline je sol UTP-a.
Prior to use, the plates are washed 3× with phosphate buffered saline solution. 
Ploče su prije upotrebe isprane 3 x fosfatno puferiranom fiziološkom otopinom.
The compound or composition of Claim 13, for administration with a second therapeutic agent selected from a second HTV protease inhibitor, a non-nucleoside reverse transcriptase inhibitor, a nucleoside/nucleotide reverse transcriptase inhibitor, a viral entry inhibitor, an integrase inhibitor, an immune based antiretroviral agent, a vital maturation inhibitor, a cellular inhibitor, or combinations of two or more of the above. 
Spoj ili kompozicija prema zahtjevu 15 za davanje s drugim terapeutskim sredstvom koje se bira od drugog inhibitora HIV proteaze, nenukleozidnog inhibitora reverzne transkriptaze, nukleozidnog/nukleotidnog inhibitora reverzne transkriptaze, inhibitora ulaska virusa, inhibitora integraze, antiretroviralnog imunološkog sredstva, inhibitora sazrijevanja virusa, staničnog inhibitora, ili kombinacija dva ili više gore navedenih.
The composition for use according to claim 19, wherein the adverse effect is chosen from the group consisting of diarrhea and abdominal bloating. 
dC ili dT, namijenjeni upotrebi u skladu s patentnim zahtjevom 20, naznačeni time što se štetni učinak bira iz skupine koju čine proljev i nadutost u trbuhu.
The table saw according to claim 14, wherein the push stick comprises a wire-bound or a wireless communication interface, via which the flat contact signal can be transmitted, and a machine controller of the table saw comprises a respective wire-bound or a respective wireless communication interface, via which the flat contact signal can be received, wherein the machine controller comprises an actuator and an actuating device for the actuator, wherein the actuating device actuates the actuator in response to when the flat contact signal signals that the sliding surface and the holding-down surface lie flat against the workpiece. 
Stolna pila u skladu s patentnim zahtjevom 8, naznačena time što potiskivač sadrži ožičeno ili po mogućnosti sučelje za bežičnu komunikaciju, putem kojeg se može poslati signal o ravnom kontaktu, a strojni upravljač stolne pile sadrži odgovarajuće ožičeno ili po mogućnosti sučelje za bežičnu komunikaciju, putem kojeg se može primiti signal o ravnom kontaktu, gdje strojni upravljač sadrži aktuator i uređaj za aktuiranje aktuatora, gdje navedeni uređaj za aktuiranje aktuira aktuator kao odgovor na to signalizira li ravni kontakt leže li ili ne klizna površina i pritisna površina ravno na predmetu obrade.
The IL-17 antagonist for use according to Claim 1, wherein the IL-17 antagonist is a bispecific antibody or bispecific antibody fragment that binds to and inhibits the activity of a) IL-17 and IL-23p19, or b) IL-17 and IL-23R. 
IL-17 antagonist za uporabu u skladu sa zahtjevom 1, naznačen time, da IL-17 antagonist je bispecifično antitijelo ili fragment bispecifičnog antitijela koje se veže na i inhibira djelovanje a) IL-17 i IL-23p19, ili b) IL-1711L-23R.
determining whether less of said complex is formed in the presence of the test compound than in the absence of the test compound; wherein said determination is indicative of the test compound being a GLP-1 secretagogues. 
(c) određivanje da li se manje navedenog kompleksa formira u prisutnosti test spoja nego li u odsutnosti test spoja; pri čemu je navedeno određivanje indikativno da je test spoj GLP-1 sekretogog.
The compound, composition or dosage form according to claim 7, wherein the cancer is selected from lung cancer including non-small cell lung cancer and small cell lung cancer, colon cancer, colorectal cancer, breast cancer, pancreas cancer, sarcoma, ovarian cancer and gastric cancer. 
Sjedinjenje, kompozicija ili dozni oblik u skladu sa patentnim zahtjevom 7, gdje je rak odabran od raka pluća uključujući rak pluća malih stanica i rak pluća nemalih stanica, rak debelog crijeva, kolorektalnog raka, raka dojke, raka gušterače, sarkoma, raka jajnika i raka želuca.
The method of paragraph 3, wherein, the increased dosage is associated with an increased risk of an adverse reaction. 
Postupak prema zahtjevu 1, pri čemu je povećana doza povezana s povećanim rizikom od neželjene reakcije.
The immunoconjugate of claim 5, wherein said linker is selected from the group consisting of a cleavable linker, a non-cleavable linker, a hydrophilic linker, and a dicarboxylic acid based linker. 
je majtanzinoid ili analog majtanzinoida. gdje navedeni vezni dio (L) povezuje (A) za (C), gdje je (A) odabran iz grupe koja se sastoji od:
a transmission unit configured to transmit a signal including the modulated signal frame. 
dio za unos intervala čuvara (503) konfiguriran za unos intervala čuvara u modulirani okvir signala;
A pharmaceutical composition as defined in claim 13 for use in a method of treating cancer. 
Farmaceutski sastav za uporabu prema zahtjevu 19, pri čemu je bolest rak.
The column was flushed with MeOH (2.0 L) to remove unbound impurities. 
Kolona je isprana sa MeOH (2.0 L) da bi se uklonila onečišćenja.
a mutated ptr gene, wherein the mutated ptr gene encodes a Protease III protein having reduced protease activity or is a knockout mutated ptr gene; and 
omutirani ptr gen, pri čemu mutirani ptr gen kodira Proteaza III protein koji ima smanjenu proteaznu aktivnost ili je nokaut mutirani ptr gen; i c.
in response to a first gain condition being satisfied, applying an exponential operation to the gain value; and in response to a second gain condition being satisfied, applying a linear operation to the gain value. 
Postupak prema zahtjevu 6, gdje slabljenje pojačanja podrazumijeva: primjenu eksponencijalne operacije na vrijednost pojačanja kao odgovor na zadovoljenje prvog stanja pojačanja; i primjenu linearne operacije na vrijednost pojačanja kao odgovor na zadovoljenje drugog stanja pojačanja.
A production method according to claim 1, characterized in that, in step (i), the temperature during the addition, optionally dropwise, of the chlorinating agent is -5°C to 5°C and the reaction temperature after the addition, optionally dropwise, of the chlorinating agent is -5°C to 5°C. 
Postupak prema zahtjevu 1, naznačen time što je u koraku (i) temperatura za vrijeme dodavanja sredstva za kloriranje -5°C do 5°C i reakcijska temperatura nakon dodavanja sredstva za kloriranje je -5°C do 5°C.
from 0 to 6% by weight of an inorganic carbonate, and veterinarily acceptable adjuvants and/or excipients. 
€) od 0 do 6 težinskih % neorganskog karbonata, veterinarski prihvatljive adjuvante i/ili inertne punitelje.
wherein permitting the second computer user to access the particular version of the particular data object is based on determining that the one or more rules do not restrict access for the second user to the particular data object as well as being based on the base set of data and a version identifier value for the one or more data objects. 
gdje revizionirajuća baza podataka povezuje svaki podatkovni objekt jednog ili više podatkovnih objekata s vrijednošću identifikatora područja i s vrijednošću identifikatora verzije za skupinu verzija podatkovnog objekta, gdje svaka od verzija predstavlja promjenu podatkovnog objekta od strane bilo kojeg od korisnika baze podataka;
The monoclonal antibody or antigen binding fragment thereof of claim 1, which binds to at least four CC chemokines selected from the group consisting of CCL3/MIP-1a, CCL4/MIP-1B, CCL5/RANTES, CCL14/HCC-1, and CCL18/PARC, and which does not bind to CCL2/MCP-1, comprising a heavy and light chain CDR sequence combination (HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3) of SEQ ID NO: 23/24/25/28/29/30, or which competes for binding to at least four CC chemokines selected from the group consisting of CCL3/MIP-1a, CCL4/MIP-1B, CCL5/RANTES, CCL4/HCC-1, and CCL18/PARC, with an antibody or antigen binding fragment comprising a heavy and light chain CDR sequence combination of SEQ ID NO: 23/24/25/28/29/30. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da se veže na najmanje četiri CC kemokina odabranih iz skupine koja se sastoji od CCL3/MIP-1a, CCL4/MIP-1B, CCL5/RANTES, CCL14/HCC-1, i CCL18/PARC, a koji se ne vežu na CCL2/MCP-1, koji sadrži kombinaciju CDR slijedova teškog i lakog lanca (HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3) od SEQ ID NO: 23/24/25/28/29/30, ili koji se natječe za vezanje na najmanje četiri CC kemokina odabranih iz skupine koja se sastoji od CCL3/MIP-1a, CCL4/MIP-1B, CCL5/RANTES, CCL4/HCC-1, i CCL18/PARC, s antitijelom ili fragmentom koji veže antigen koji sadrži kombinaciju CDR slijedova teškog i lakog lanca SEQ ID NO: 23/24/25/28/29/30.
The compound according to claim 1, wherein ring B and the pyrimidine to which it is fused form a ring system selected from the group consisting of 
Spoj prema zahtjevu 1 ili 2, naznačen time da prsten B i pirimidin na koji je kondenziran tvore prstenasti sustav odabran od
In certain embodiments, the Omega-3 fatty acid esters in said composition comprise Omega-3 fatty acid esters. In certain embodiments, the EPA and DHA esters constitute at least from about 40% to about 95% of the total Omega-3 fatty acid esters of the composition. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 9, naznačen time što navedeni etilni esteri EPA i DHA kombinirani čine od 40 % (tež./tež.) do 95 % (tež./tež.) ukupnih estera omega-3 masnih kiselina u navedenom pripravku.
They may be administered alone or in combination with one or more other compounds of the invention or in combination with one or more other drugs (or as any combination thereof). 
DN pri čemu sustav prstena u cjelini može biti supstituiran s jednom 1li više od sljedećih skupina: C,galkil ili (CH2),C3. zcikloalkil.
posaconazole, wherein posaconazole is selected from crystalline form III of posaconazole or amorphous posaconazole or a mixture thereof; and water or a mixture of water and methanol; and allowing the posaconazole to transform to crystalline form IV at a temperature of at most 60 °C. 
(1) posakonazola, pri čemu je posakonazol odabran od kristalnog oblika II posakonazola ili amorfnog posakonazola ili njihove mješavine; 1 (1i) vode ili mješavine vode i metanola; i (b) dopuštanje pretvorbe posakonazola u kristalni oblik IV na temperaturi od najviše 60%C.
The method according to claim 14, further including reacting an antioxidant compound with a linker, wherein after reacting the antioxidant compound with the linker, a reduction is performed. 
Postupak u skladu s patentnim zahtjevom 12, naznačen time što se nakon reakcije antioksidantnog spoja sa spojnicom provodi korak redukcije.
a communication server (1), provided for sending and receiving messages over a telecommunication network (2), 
- < komunikacijski server (1) za slanje i primanje poruka preko telekomunikacijske mreže (2),
The pharmaceutical formulation of claim 11, wherein at least 96% of the native form of said antibody is recovered after nine months of storage at 5° C., as determined by size exclusion-high performance liquid chromatography (SE-HPLC). The pharmaceutical formulation of claim 9, wherein the formulation exhibits a viscosity of less than about 15 cPoise. 
Farmaceutski pripravak prema patentnom zahtjevu 1 ili 2, naznačen time, što se najmanje 96 % izvornog oblika spomenutog antitijela dobiva nakon devetomjesečne pohrane na temperaturi od 5 °C, što se utvrđuje pomoću visokoučinkovite tekućinske kromatografije isključivanja po veličini (SE-HPLC).
Stirred at room temperature for 3h, then the reaction mixture was poured into water (150 mL) and extracted with ethyl acetate. 
Miješa se na sobnoj temperaturi kroz 3 sata, potom se reakcijska smjesa prelije preko vode (150 ml) i ekstrahira s etil acetatom.
represents a monocyclic or a fused-bicyclic aromatic or hetero-aromatic group, which groups are unsubstituted or substituted with one or more substituents Y, as defined above or R8 represents an -CR9=CR10-aryl group wherein R9 and R10 independently represent hydrogen or an alkyl-(C1-3) group, and wherein 'aryl' comprises monocyclic or fused bicyclic aromatic or hetero-aromatic groups, or R8 represents an -C≡C-aryl group, wherein 'aryl' has the abovementioned meaning, a piperidinyl group unsubstituted or substituted with one or more substituents Y, as defined above, or a group -NR11R12, wherein R11 and R12 independently represent hydrogen, an unsubstituted alkyl-(C1-3) group or a phenyl or benzyl group, which phenyl or benzyl groups are unsubstituted or substituted with one or more substituents Y, as defined above. 
predstavlja monocikličku ili sjedinjenu-bicikličku aromatičnu ili hetero- aromatičnu skupinu, gdje su te skupine nesupstituirane ili supstituirane s jednim ili više Y supstituenata, koji su prethodno određeni, ili R8 predstavlja –CR9=CR10-arilnu skupinu gdje R9 i R10 neovisno predstavljaju vodik ili alkil-(C1-3) skupinu, i gdje ’aril’ obuhvaća monocikličke ili sjedinjene-bicikličke aromatične ili hetero-aromatične skupine, ili R8 predstavlja -C≡C-arilnu skupinu, gdje ’aril’ ima gore navedeno značenje, piperidinil skupinu nesupstituiranu ili supstituiranu s jednim ili više Y supstituenata, koji su prethodno određeni, ili skupinu –NR11R12, gdje R11 i R12 neovisno predstavljaju vodik, nesupstituiranu alkil-(C1-3) skupinu ili fenilnu ili benzilnu skupinu, pri čemu su fenilna iii benzilna skupina nesupstituirane ili supstituirane s jednim ili više Y supstituenata, koji su prethodno određeni.
II)induced by Nontypeable Haemophilus influenza; or 
Il) izazvano netipičnom hemofilus influencom; ili
The inventive pharmaceutical composition may be compiled such that the selection, number and/or amount of peptides present in the composition is/are tissue, cancer, and/or patient-specific. 
Farmaceutski sastav prema bilo kojem zahtjevu od 1 do 3, gdje je odabir, broj i/ili količina peptida prisutnih u sastavu specifičan za tkivo, karcinom i/ili pacijenta.
A composition comprising the antibody of claim 2 wherein said antibody is at least 95% by mass of the total antibody mass of said composition. 
Kompozicija koja sadrži antitijelo iz bilo kojeg od patentnih zahtjeva 1 do 8 gdje spomenuto antitijelo je najmanje 95% po masi ukupne mase antitijela spomenute kompozicije.
at least one binder, and 
- barem jedno vezivno sredstvo, te
An injection assembly according to claim 6 or 7, wherein the fixed containment wall (556) and the movable containment wall (546) axially overlap by a length, leaving a free gap for the passage of fluid from the inside to the outside of the case and vice versa. 
Injekcijski sklop u skladu s patentnim zahtjevom 6 ili 7, naznačen time što se stijenka fiksnog spremišta (556) i stijenka pokretnog spremišta (546) aksijalno preklapaju po duljini, što ostavlja slobodni razmak za prolaženje fluida od unutrašnjosti prema vanjštini kućišta i obratno.
The use of claim 12, wherein N-acetylglucosamine and the alkaline metal sulphate are in the equivalent weight ratio of 1:1. 
Uporaba skladu s patentnim zahtjevom 12, naznačena time, da su N-acetilglukozamin i sulfat alkalnih metala u ekvivalentnim težinskom odnosu 1:1.
A method according to claim 5, wherein monitoring and controlling the moisture of the sludge during the treatment with said superheated steam is effected in such a way that the moisture of the material changes in the treatment by +/−2% at most to prevent substantial drying of the sludge. 
6. Metoda u skladu s patentnim zahtjevom 5, karakterizirana praćenjem i nadziranjem vlažnosti mulja za vrijeme tretiranja superzagrijanom parom na način da se vlažnost materijala tijekom tretiranja mijenja najviše +2% zbog sprječavanja sadržajnog isušivanja mulja.
The inventors have detected that the processing of the respective adhesion surfaces of the board-like, plane pieces of wood has, prior to the gluing, a considerable importance in the scope of the present invention. 
Izumitelji su otkrili da obrada odgovarajuće površine za lijepljenje ravnog komada od drva koji ima oblik ploče prije lijepljenja ima značajnu važnost u djelokrugu ovog izuma.
Number of experiments D-Mannitol * 
Broj međunarodne prijave:
is RE, -OH, -NH2, -N(CH3)2, or -N+(CH3)3; or RD1 and RD2, taken together with atoms to which they are attached, form a 3-8 membered saturated, partially unsaturated, or aromatic ring with up to 3 ring members independently selected from the group consisting of O and NRE; and 
Ro je R", -OH, -NHL, -N(CH3),, ili -N'(CH>)s; ili RD! i R?Ž, uzeti zajedno s atomima na koje su vezani, tvore 3-8 člani zasićeni, djelomično nezasićeni, ili aromatski prsten s do 3 člana prstena neovisno odabrana iz skupine koju čine O i NR i
A casting belt (12, 14) adapted for use in a continuous casting apparatus characterized in that said casting belt has a thickness of 1 to 2 mm and is made of an aluminum alloy selected from AA5XXX and AA6XXX alloy systems. 
Remen za lijevanje (12, 14) prilagođen za upotrebu u uređaju za neprekidno lijevanje, naznačen time da navedeni remen za lijevanje ima debljinu od 1 do 2 mm i da je napravljan od legure aluminija odabrane od AA5XXX i AA6XXX sistema legura.
In vitro release of the active ingredient was determined as in Example 1 and was: Time Released quantity 
Oslobađanje djelatne tvari in-vitro određeno je kao u Primjeru 1 i iznosilo je: Vrijeme
For purposes of the teaching of the present teachings: 
Datum podnošenja europske prijave patenta: